Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BIA

ABPI London offices

ABPI bid to overturn NICE’s budget impact rules fails

One in five new medicines would have been affected by the rejected policy

- PMLiVE

NICE: We’re the institute of ‘yes’

But Meindert Boysen says affordability conversations with pharma need to happen earlier

- PMLiVE

Vertex poaches new finance chief from Ironwood Pharmaceuticals

Boston-based biotech company appoints Tom Graney

- PMLiVE

Vertex hits sweet spot with triple cystic fibrosis therapy

The new treatment could benefit up to 90% of patients with CF

UK flag

Mixed news for pharma on UK’s Accelerated Access Review

New funding will go towards ASHNs, SME’s and the Pathway Transformation Fund to name a few

- PMLiVE

Vertex strikes Italian reimbursement deal for Orkambi

AIFA gives the go-ahead for the cystic fibrosis treatment

- PMLiVE

EU and UK pharma leaders appeal directly to Brexit negotiators

EFPIA, ABPI and BIA warn Michel Barnier and David Davies an unorderly withdrawal could hit medicine supplies

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

- PMLiVE

UK signals desire for close post-Brexit relationship with EU

Health and business ministers outline areas where collaboration may continue

- PMLiVE

FDA broadens use of cystic fibrosis drug Kalydeco

Drug now available to more patients in the US

- PMLiVE

UK pharma apprehensive about post-Brexit investment

ABPI calls for a return of the 'white heat' of innovation to the UK

ABPI London offices

UK pharma calls on next government to be more ambitious

ABPI wants medicines access to reach levels of other developed nations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links